Apimeds Pharmaceuticals US, Inc. APUS
$7.25
+47.36%
at last close
Recent SEC Filings
| Form | Description | Filed | Document |
|---|---|---|---|
| 8-K | CURRENT REPORT | 2026-09-23 | View → |
| 8-K | CURRENT REPORT | 2026-09-11 | View → |
| 8-K | CURRENT REPORT | 2026-08-21 | View → |
| 10-Q | QUARTERLY REPORT | 2026-08-14 | View → |
| 8-K | CURRENT REPORT | 2026-08-06 | View → |
| 8-K | CURRENT REPORT | 2026-07-13 | View → |
| 10-Q | QUARTERLY REPORT | 2026-05-26 | View → |
| 8-K | CURRENT REPORT | 2026-05-05 | View → |
| 10-K | ANNUAL REPORT | 2026-05-04 | View → |
| 8-K | CURRENT REPORT | 2026-05-04 | View → |
| 8-K | FORM 8-K | 2026-04-22 | View → |
| 8-K | CURRENT REPORT | 2026-04-16 | View → |
| 8-K | CURRENT REPORT | 2026-03-26 | View → |
| 8-K | CURRENT REPORT | 2026-03-25 | View → |
| 8-K | CURRENT REPORT | 2026-03-16 | View → |
| 8-K | CURRENT REPORT | 2026-01-02 | View → |
| 8-K | CURRENT REPORT | 2025-12-10 | View → |
| 8-K | CURRENT REPORT | 2025-12-02 | View → |
| 8-K | CURRENT REPORT | 2025-11-18 | View → |
| 4 | PRIMARY DOCUMENT | 2025-11-13 | View → |
| 4 | PRIMARY DOCUMENT | 2025-11-13 | View → |
| 4 | PRIMARY DOCUMENT | 2025-11-13 | View → |
| 4 | PRIMARY DOCUMENT | 2025-11-13 | View → |
| 4 | PRIMARY DOCUMENT | 2025-11-13 | View → |
| 10-Q | QUARTERLY REPORT | 2025-11-12 | View → |
| 4 | PRIMARY DOCUMENT | 2025-10-24 | View → |
| 4 | PRIMARY DOCUMENT | 2025-10-21 | View → |
| 4 | PRIMARY DOCUMENT | 2025-10-17 | View → |
| 4 | PRIMARY DOCUMENT | 2025-10-17 | View → |
| 4 | PRIMARY DOCUMENT | 2025-10-17 | View → |
| 4 | PRIMARY DOCUMENT | 2025-10-17 | View → |
| 4 | PRIMARY DOCUMENT | 2025-10-17 | View → |
| 8-K | CURRENT REPORT | 2025-10-16 | View → |
| 10-Q | QUARTERLY REPORT | 2025-08-19 | View → |
| 8-K | CURRENT REPORT | 2025-07-16 | View → |
| 8-K | CURRENT REPORT | 2025-06-05 | View → |
| 4 | PRIMARY DOCUMENT | 2025-05-20 | View → |
| 4 | PRIMARY DOCUMENT | 2025-05-20 | View → |
| 4 | PRIMARY DOCUMENT | 2025-05-20 | View → |
| 4 | PRIMARY DOCUMENT | 2025-05-20 | View → |
Filings are sourced directly from the SEC's EDGAR system. Annual reports (10-K) and quarterly reports (10-Q) carry the full financial statements; 8-K filings disclose material events between reports; Form 4 filings record insider purchases and sales.
Key Stats
- Last Close
- $7.25
- Market Cap
- $7.42 million
- 52-Week Range
- $1.51 – $59.70
- Average Volume
- 4.35 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.